Coherus Biosciences (CHRS – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst on January 19. Analyst Douglas Tsao from H.C. Wainwright remains neutral on the stock and has a $13.00 price target.
Douglas Tsao has given his Buy rating due to a confluence of promising clinical data and strategic asset positioning within Coherus Biosciences’ portfolio. The compelling early activity data from the Phase 2 trial of casdozo in combination therapy for liver cancer, which shows a 38% overall response rate and an 8.1-month median progression-free survival, underscores the potential of Coherus’ pipeline. Furthermore, casdozo’s unique positioning as the only IL-27 targeting antibody in development, coupled with the plan to incorporate toripalimab in upcoming trials, strengthens the company’s immuno-oncology offerings.
The valuation underpinning the Buy rating and the $13 price target is rooted in a detailed sum-of-the-parts net present value assessment of Coherus’ diverse product pipeline. Tsao’s financial model accounts for varying probabilities of success across the company’s assets, including fully commercialized treatments and those still in development. Despite recognizing certain risks such as regulatory hurdles, market competition, and potential intellectual property disputes, the analyst’s outlook remains positive, reflecting confidence in the company’s strategic direction and product portfolio.
According to TipRanks, Tsao is a 4-star analyst with an average return of 6.9% and a 41.77% success rate. Tsao covers the Healthcare sector, focusing on stocks such as Coherus Biosciences, Apellis Pharmaceuticals, and Marinus.
See today’s best-performing stocks on TipRanks >>
TipRanks tracks over 100,000 company insiders, identifying the select few who excel in timing their transactions. By upgrading to TipRanks Premium, you will gain access to this exclusive data and discover crucial insights to guide your investment decisions. Begin your TipRanks Premium journey today.
Coherus Biosciences (CHRS) Company Description:
Coherus BioSciences, Inc. is a commercial-stage clinical biologics platform company, which engages in the development and commercialization of biosimilar therapeutics. Its clinical products include pegfilgrastim biosimilar, adalimumab biosimilar, etanercept biosimilar, ranibizumab biosimilar, and aflibercept biosimilar. The company was founded by Dennis M. Lanfear, Stuart E. Builder, Dr. Alan Herman, Doug Farrar and Steve Glover in September 2010 and is headquartered in Redwood City, CA.
Read More on CHRS:
- M & A News: Coherus (NASDAQ:CHRS) Surges after $170M Deal with Sandoz
- Coherus Announces Agreement to Divest Ophthalmology Franchise to Sandoz in $170 Million Upfront All Cash Deal
- Coherus Biosciences presents positive Phase 2 data on casdozokitu
- Coherus Presents Positive Phase 2 Clinical Data on Casdozokitug, a First-in-Class IL-27-Targeted Antibody, at the 2024 ASCO GI Cancers Symposium
- Inovio, Coherus Biosciences announces clinical collaboration
